Investor Update
Basel, 26 November 2008
Anti-malignancy agent / anti-VEGF humanised monoclonal antibody, Avastin
Application for Approval of Additional Indication of NSCLC
Basel, 26 November 2008
Anti-malignancy agent / anti-VEGF humanised monoclonal antibody, Avastin
Application for Approval of Additional Indication of NSCLC